Currently in Chapter 11, Natural Molecular Testing Will Shut Down, Repay CMS $71M | GenomeWeb

NEW YORK (GenomeWeb) – Natural Molecular Testing, currently in Chapter 11 reorganization, has reached a settlement with the Centers for Medicare and Medicaid Services to pay back the agency $71.1 million in overpayments received by NMT. 

In court documents filed on Thursday in US Bankruptcy Court, Western District of Washington at Seattle, the trustee for NMT said the firm will cease all operations, end its plans to reorganize, and liquidate its assets. 

Under the terms of the settlement, NMT will begin repaying CMS after it has paid other creditors $1 million. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The White House has created a list of cuts, including to the NIH, that could be in a budget bill for this year.

The US National Institutes of Health is to allow applicants to cite preprints just as they would any other research paper, ScienceInsider reports.

Two manuscript pages handwritten by Charles Darwin are going on the auction block, according to the Los Angeles Times.

In PNAS this week: tool to track transcriptome-wide binding, evidence of balancing selection on behavior-linked genes, and more.

Mar
30
Sponsored by
SeraCare

Our roundtable of industry experts will provide an overview of the current regulatory landscape for clinical genomics tests.

Apr
13
Sponsored by
SeraCare

In this webinar, Gregory J. Tsongalis of Dartmouth Hitchcock Medical Center will discuss how his lab developed and validated a cancer hotspot assay. 

Apr
18
Sponsored by
Twist BioScience

This webinar will cover methodologies for genome-wide screening with CRISPR/Cas9 in human pluripotent stem cells (hPSCs) and their neuronal progeny.

Apr
27
Sponsored by
SeraCare

This webinar is the third in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.